The combination of SHP2 inhibitor and anti-PD1 antibody has also shown to CD8 + T cell recruitment, a decrease in myeloid derived suppressive cells, and heightened anti-tumour immunity in mouse models [166, 167]. The gene discussed is PTPN11; the disease is neoplasm.